This is the second year in a row a TOI
physician was recognized
The Oncology Institute (TOI) is proud to announce that Dr. John
Khoury was recently awarded the “40 Under 40 in Cancer” award by
the Association for Value-Based Cancer Care. This is the second
year in a row a TOI physician was recognized for this honor. Dr.
Omkar Marathe was selected for the distinction in 2020.
"It’s an honor to be part of such a distinguished list of young
oncology professionals and leaders who work very hard to improve
the lives of those affected by cancer," said Dr. Khoury.
Dr. John Khoury is a triple board-certified physician who joined
The Oncology Institute in 2020. He completed his residency and
fellowship at Oakland University William Beaumont School of
Medicine in Detroit, where he specialized in hematology and
oncology.
“Dr. Khoury is a compassionate provider and collaborative
colleague,” shared TOI CMO Dr. Yale Podnos. “He also serves as a
Principal Investigator on several clinical trials, and his patients
benefit from his passion for cancer research.”
This award recognizes Dr. Khoury's dedication to providing the
best care to his patients and continuous efforts to put them first.
He serves patients at TOI’s Glendale and Pasadena locations. The
“40 Under 40 in Cancer” Award is presented by The Lynx Group,
Upstream Partners, the Association for Value-Based Cancer Care,
NCODA, and Swim Across America.
TOI announced its intent to become a publicly traded company via
a business combination with DFP Healthcare (NASDAQ: DFPH, DFPHW) in
June. A special meeting of shareholders to approve the business
combination is scheduled for Friday, November 12th, at 10am
EST.
About The Oncology Institute
Founded in 2007, The Oncology Institute of Hope and Innovation
(TOI) is advancing oncology by delivering highly specialized,
value-based cancer care in the community setting. TOI is dedicated
to offering cutting-edge, evidence-based cancer care to a
population of more than 1.5 million patients including clinical
trials, stem cell transplants, transfusions, and other care
delivery models traditionally associated with the most advanced
care delivery organizations. With 80+ employed clinicians and more
than 600 teammates in 50 clinic locations and growing, TOI is
changing oncology for the better. For more information visit
www.theoncologyinstitute.com.
Important Information and Where to Find
It
In connection with the proposed Business Combination, DFP has
filed a registration statement on Form S-4 (the “Registration
Statement”) with the Securities and Exchange Commission (the
“SEC”), which includes a proxy statement/prospectus and certain
other related documents, that is both the proxy statement to be
distributed to holders of shares of DFP common stock in connection
with DFP’s solicitation of proxies for the vote by DFP’s
stockholders with respect to the Business Combination and other
matters as may be described in the Registration Statement, as well
as the prospectus relating to the offer and sale of securities of
DFP to be issued in the Business Combination.
The Registration Statement was declared effective by the SEC on
October 22, 2021 and DFP will mail the definitive proxy
statement/prospectus and other relevant documents to its
stockholders as of the Record Date. DFP’s stockholders, and other
interested persons are advised to read the definitive proxy
statement/prospectus and other documents filed in connection with
the proposed Business Combination, as these materials contain
important information about DFP, TOI and the Business Combination.
DFP stockholders and TOI stockholders may also obtain copies of the
definitive proxy statement/prospectus and other documents filed
with the SEC, without charge at the SEC’s website at www.sec.gov,
or by directing a request to: DFP Healthcare Acquisitions Corp. at
its principal executive offices 345 Park Avenue South, New York, NY
10010.
Participants in the
Solicitation
DFP and its directors and executive officers may be deemed
participants in the solicitation of proxies from DFP’s stockholders
with respect to the proposed Business Combination. A list of the
names of those directors and executive officers and a description
of their interests in DFP is contained in the definitive proxy
statement/prospectus and is available free of charge at the SEC’s
web site at www.sec.gov, or by directing a request to DFP
Healthcare Acquisitions Corp. at its principal executive offices
345 Park Avenue South New York, New York 10010. Additional
information regarding the interests of such participants is
contained in the Registration Statement.
TOI’s directors and executive officers may also be deemed to be
participants in the solicitation of proxies from the stockholders
of DFP in connection with the Business Combination. A list of the
names of such directors and executive officers and information
regarding their interests in the Business Combination is included
in the Registration Statement.
Forward-Looking Statements
This communication includes certain statements that are not
historical facts but are forward-looking statements for purposes of
the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking
statements generally are accompanied by words such as “believe,”
“may,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
“expect,” “should,” “would,” “plan,” “predict,” “potential,”
“seem,” “seek,” “future,” “outlook,” and similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. These forward- looking statements
include, but are not limited to, statements regarding projections,
estimates and forecasts of revenue and other financial and
performance metrics and projections of market opportunity and
expectations, the expectation that DFP’s common stock will continue
to be listed on Nasdaq, and the anticipated special meeting date
and closing date of the proposed Business Combination. These
statements are based on various assumptions and on the current
expectations of DFP and TOI and are not predictions of actual
performance. These forward-looking statements are provided for
illustrative purposes only and are not intended to serve as, and
must not be relied on by any investor as, a guarantee, an
assurance, a prediction or a definitive statement of fact or
probability. Actual events and circumstances are difficult or
impossible to predict and will differ from assumptions. Many actual
events and circumstances are beyond the control of DFP and TOI.
These forward-looking statements are subject to a number of risks
and uncertainties, including the outcome of judicial and
administrative proceedings to which DFP following the Business
Combination (hereafter, “The Oncology Institute”) may become a
party or governmental investigations to which The Oncology
Institute may become subject that could interrupt or limit The
Oncology Institute’s operations, result in adverse judgments,
settlements or fines and create negative publicity; changes in The
Oncology Institute’s clients’ preferences, prospects and the
competitive conditions prevailing in the healthcare sector; the
inability of the parties to successfully or timely consummate the
proposed Business Combination, including the risk that any required
regulatory approvals are not obtained, are delayed or are subject
to unanticipated conditions that could adversely affect the
combined company or the expected benefits of the proposed Business
Combination or that the approval of the stockholders of DFP and/or
the equity holders of TOI for the proposed Business Combination is
not obtained; failure to meet stock exchange listing standards
following the consummation of the Business Combination; costs
related to the Business Combination; failure to realize the
anticipated benefits of the proposed Business Combination,
including as a result of a delay in consummating the proposed
Business Combination or a delay or difficulty in integrating the
businesses of DFP and TOI; the amount of redemption requests made
by DFP’s stockholders; the impact of COVID-19 on the combined
company’s business and/or the ability of the parties to complete
the proposed Business Combination; those factors discussed in the
Registration Statement under the heading “Risk Factors,” and other
documents of DFP filed, or to be filed, with the SEC. If the risks
materialize or assumptions prove incorrect, actual results could
differ materially from the results implied by these forward-looking
statements. There may be additional risks that neither DFP nor TOI
presently know or that DFP and TOI currently believe are immaterial
that could also cause actual results to differ from those contained
in the forward-looking statements. In addition, forward- looking
statements reflect DFP’s and TOI’s expectations, plans or forecasts
of future events and views as of the date of this press release.
DFP and TOI anticipate that subsequent events and developments will
cause DFP’s and TOI’s assessments to change. DFP and TOI do not
undertake any obligation to update any of these forward- looking
statements. These forward-looking statements should not be relied
upon as representing DFP’s and TOI’s assessments as of any date
subsequent to the date of this press release. Accordingly, undue
reliance should not be placed upon the forward-looking
statements.
Non-Solicitation
This communication is for informational purposes only and shall
not constitute a solicitation of a proxy, consent or authorization
with respect to any securities or in respect of the proposed
Business Combination and shall not constitute an offer to sell or a
solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any state or jurisdiction in which such
offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of such
state or jurisdiction. No offering of securities shall be made
except by means of a prospectus meeting the requirements of Section
10 the Securities Act of 1933, or an exemption therefrom.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211109005525/en/
Julie Korinke Director, Marketing and Communications
562.735.3226 x.88806 juliekorinke@theoncologyinstitute.com
DFP Healthcare Acquisiti... (NASDAQ:DFPH)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
DFP Healthcare Acquisiti... (NASDAQ:DFPH)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
